ASCO GU 2020: Overall survival results for savolitinib and durvalumab in papillary kidney cancer
Overall survival results from a study with a combination of [...]
ASCO GU 2020: Five-year survival data for metastatic kidney cancer patients treated with nivolumab
Five-year follow-up results from the phase 3 CheckMate-025 study, which [...]
First-line treatment of papillary renal cell carcinoma with sunitinib
Papillary renal cell carcinoma (PRCC) is a rare subtype of [...]
Real-world clinical outcomes with first-line sunitinib for metastatic kidney cancer
A paper published in The Oncologist last month analysed real-world [...]
A potential biomarker for survival for non-metastatic kidney cancer
A recent study published in the journal International Urology and [...]
Long-term risk of recurrence after surgery for kidney cancer
A recent study published in the journal European Urology investigated [...]
Long term survival after radiofrequency ablation for kidney cancer
A study published in the Journal of Vascular and Interventional [...]
Bone-targeted therapies may improve survival in metastatic kidney cancer patients
A recent study published in the journal Translational Oncology suggests [...]
Body mass index may impact survival in patients with kidney cancer
A recent paper published in the journal Lancet Oncology provides [...]
Radiofrequency ablation and systemic treatment for kidney cancer lung metastases
A recent study published in BMC Cancer reports on the [...]
